Palavras-chave
Saúde Sexual
Disfunções Sexuais Fisiológicas
Testosterona
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar a saúde sexual feminina na pós-menopausa, destacando alterações hormonais, fisiológicas e repercussões psicossociais associadas a esse período. Revisão bibliográfica: A saúde sexual feminina sofre impacto significativo após a menopausa, principalmente em decorrência do hipoestrogenismo e da redução progressiva dos níveis androgênicos relacionados ao envelhecimento. Essas alterações hormonais contribuem para modificações estruturais e funcionais no trato geniturinário, frequentemente associadas à Atrofia Vulvovaginal (AVV) e à Síndrome Geniturinária da Menopausa (SGUM). Tais condições estão relacionadas a sintomas como secura vaginal, dispareunia, diminuição da lubrificação e redução do desejo sexual, fatores que podem comprometer a satisfação sexual e a qualidade de vida das mulheres. Além dos aspectos biológicos, fatores psicossociais e relacionais também desempenham papel relevante na ocorrência da Disfunção Sexual Feminina (DSF), evidenciando seu caráter multifatorial. Considerações finais: A saúde sexual na pós-menopausa deve ser compreendida de forma integral, considerando a interação entre fatores hormonais, físicos e psicossociais. O reconhecimento dessas alterações e a adoção de abordagens terapêuticas individualizadas são fundamentais para promover bem-estar, autonomia e melhor qualidade de vida às mulheres nessa fase da vida.
Referências
MONTERO AA e CARNERERO CIS. Disfunción sexual femenina: opciones de tratamiento farmacológico. SEMERGEN - Medicina de Família, 2016; 42(5): e33–e37.
AMERICAN PSYCHIATRIC ASSOCIATION. Manual diagnóstico e estatístico de transtornos mentais – DSM-5. 5 ed. Porto Alegre: Artmed, 2014.
BASSON R. The female sexual response: a different model. Journal of Sex & Marital Therapy, 2000; 26(1): 51–65.
BIANCHI VE, et al. The role of androgens in women’s health and wellbeing. Pharmacological Research, 2021; 171: 105758.
BRASIL APA e ABDO CHN. Transtornos sexuais dolorosos femininos. Revista Diagnóstico & Tratamento, 2016; 21(2): 89–92.
BRAUNSTEIN GD, et al. Testosterone reference ranges in normally cycling healthy premenopausal women. The Journal of Sexual Medicine, 2011; 8(10): 2924–2934.
BURGER HG. Androgen production in women. Fertility and Sterility, 2002; 77: 3–5.
CASSON P. Effect of postmenopausal estrogen replacement on circulating androgens. Obstetrics & Gynecology, 1997; 90(6): 995–998.
CHAIKITTISILPA S, SOIMONGKOL K, JAISAMRARN U. Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women. Climacteric, 2019; 22(5): 460–465.
CUNHA GR, et al. Development of the human female reproductive tract. Differentiation, 2018; 103: 46–65.
DAVISON SL, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. The Journal of Clinical Endocrinology & Metabolism, 2005; 90(7): 3847–3853.
DAVIS SR, et al. Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine, 2008; 359(19): 2005–2017.
FABRICIO AMF, et al. Prevalence and factors associated with sexual dysfunction in Brazilian women: a cross-sectional study. International Urogynecology Journal, 2023; 34(10): 2507–2511.
FAUBION SS, et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022; 29(7): 767–794.
GANESAN K, et al. Transdermal testosterone in female hypoactive sexual desire disorder: a rapid qualitative systematic review using grading of recommendations assessment, development and evaluation. Cureus, 2018.
GUAY A, et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction. International Journal of Impotence Research, 2004; 16(2): 121–129.
INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA. Em 2022, expectativa de vida era de 75,5 anos. 2023. Disponível em: https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/38455-em-2022-expectativa-de-vida-era-de-75-5-anos.
JUDD HL, et al. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology, 1974; 118(6): 793–798.
KIM HK, et al. The recent review of the genitourinary syndrome of menopause. Journal of Menopausal Medicine, 2015; 21(2): 65.
KINGSBERG SA, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE survey. The Journal of Sexual Medicine, 2013; 10(7): 1790–1799.
KRAPF JM e SIMON JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas, 2009; 63(3): 213–219.
KRAPF JM e SIMON JA. A sex-specific dose-response curve for testosterone: could excessive testosterone limit sexual interaction in women? Menopause, 2017; 24(4): 462–470.
LARA LADS, et al. Challenges of prescribing testosterone for sexual dysfunction in women. Revista Brasileira de Ginecologia e Obstetrícia, 2024; 46: e-FPS07.
LEVINE KB, et al. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause, 2008; 15(4): 661–666.
MORAL E, et al. Genitourinary syndrome of menopause: prevalence and quality of life in Spanish postmenopausal women. Climacteric, 2018; 21(2): 167–173.
NAPPI RE e KOKOT-KIEREPA M. Vaginal health: insights, views & attitudes (VIVA) – results from an international survey. Climacteric, 2012; 15(1): 36–44.
NAPPI RE e PALACIOS S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric, 2014; 17(1): 3–9.
ZHAO X, et al. Determining the normal cut-off levels for hyperandrogenemia in Chinese women of reproductive age. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2011; 154(2): 187–191.
NAPPI RE, et al. The CLOSER survey: implications of vaginal discomfort in postmenopausal women and in male partners. The Journal of Sexual Medicine, 2013; 10(9): 2232–2241.
PARISH SJ, et al. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Journal of Women’s Health, 2021; 30(4): 474–491.
PÉREZ-HERREZUELO I, et al. Female sexual function and its association with the severity of menopause-related symptoms. International Journal of Environmental Research and Public Health, 2020; 17(19): 7235.
POMPEI LM, et al. Vaginal health: insights, views & attitudes survey in Latin America (VIVA-LATAM): focus on Brazil. Climacteric, 2021; 24(2): 157–163.
POMPEI LM, et al. Impact of postmenopausal vaginal discomfort on sex and relationships in Brazil: the CLOSER survey. Climacteric, 2021; 24(6): 593–599.
SIMON J, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of Clinical Endocrinology & Metabolism, 2005; 90(9): 5226–5233.
SIMON JA, et al. The role of androgens in the treatment of genitourinary syndrome of menopause: ISSWSH expert consensus panel review. Menopause, 2018; 25(7): 837–847.
SOCIEDADE BRASILEIRA DE CLIMATÉRIO. Consenso brasileiro multidisciplinar de assistência à saúde da mulher climatérica. 2008.
TRAISH AM, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sexual Medicine Reviews, 2018; 6(4): 558–571.
VIGNESWARAN K e HAMODA H. Androgens in postmenopausal women. The Obstetrician & Gynaecologist, 2022; 24(4): 228–241.
WÅHLIN-JACOBSEN S, et al. Is there a correlation between androgens and sexual desire in women? The Journal of Sexual Medicine, 2015; 12(2): 358–373.
WEISS RV, et al. Testosterone therapy for women with low sexual desire: a position statement from the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2019; 63(3): 190–198.